Want to see HK:3390 full AI Analyst Report?
3390 Stock Chart & Stats
HK$0.29
HK$0.01(0.29%)
At close: 4:00 PM EST
HK$0.29
HK$0.01(0.29%)
Day’s Range― - ―
52-Week RangeHK$0.22 - HK$0.39
Previous CloseN/A
Volume590.00K
Average Volume (3M)1.30M
Market Cap
HK$206.51M
Enterprise ValueHK$573.17M
Total Cash (Recent Filing)HK$70.34M
Total Debt (Recent Filing)HK$428.05M
Price to Earnings (P/E)13.2
Beta0.08
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield28%
Share Statistics
EPS (TTM)0.02
Shares Outstanding894,000,000
10 Day Avg. Volume1,126,200
30 Day Avg. Volume1,299,466
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.44
Price to Sales (P/S)0.22
P/FCF Ratio2.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Cash RecoveryA clear rebound in 2025 revenue alongside a return to positive operating and free cash flow indicates renewed demand and improved cash generation. Durable cash inflows strengthen liquidity for working capital, inventory funding and debt servicing, enabling reinvestment in distribution capabilities over months.
Defensive Distribution ModelA core business of pharmaceutical distribution to hospitals, clinics and pharmacies creates recurring, defensive revenue driven by essential healthcare demand. Ownership of logistics, sales and marketing provides durable customer relationships and execution barriers versus ad-hoc resellers, supporting steady volumes over 2–6 months.
Strengthened Capital BaseAn expanded equity base improves the firm's financial cushion and capacity to fund working capital needs typical in distribution. Higher equity reduces reliance on short-term funding, facilitating inventory financing and operational continuity through near-term industry cycles or demand fluctuations.
Bears Say
Thin ProfitabilityPersistently low and declining margins constrain the company's ability to absorb cost increases or competitive price pressure. With slim operating and net margins, incremental revenue yields little incremental profit, limiting internal financing for growth and leaving returns vulnerable to margin compression over months.
Rising LeverageLeverage rising materially since 2023 increases fixed financing obligations and reduces balance-sheet flexibility. Combined with thin margins and volatile cash flows, higher debt elevates refinancing and interest-rate risk, constraining strategic investments and increasing vulnerability over the medium term.
Volatile Earnings & Cash FlowSignificant year-to-year swings in profitability and cash generation undermine predictability of free cash flow, complicating inventory planning and credit terms with suppliers. This volatility raises execution risk for a distribution business that depends on steady working capital cycles over the next several months.
Tycoon Group Holdings Limited News
3390 FAQ
What was Tycoon Group Holdings Limited’s price range in the past 12 months?
Tycoon Group Holdings Limited lowest stock price was HK$0.22 and its highest was HK$0.39 in the past 12 months.
What is Tycoon Group Holdings Limited’s market cap?
Tycoon Group Holdings Limited’s market cap is HK$206.51M.
When is Tycoon Group Holdings Limited’s upcoming earnings report date?
Tycoon Group Holdings Limited’s upcoming earnings report date is Aug 28, 2026 which is in 19 days.
How were Tycoon Group Holdings Limited’s earnings last quarter?
Tycoon Group Holdings Limited released its earnings results on Mar 31, 2026. The company reported HK$0.026 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.026.
Is Tycoon Group Holdings Limited overvalued?
According to Wall Street analysts Tycoon Group Holdings Limited’s price is currently Overvalued.
Does Tycoon Group Holdings Limited pay dividends?
Tycoon Group Holdings Limited pays a Notavailable dividend of HK$0.035 which represents an annual dividend yield of 28%. See more information on Tycoon Group Holdings Limited dividends here
What is Tycoon Group Holdings Limited’s EPS estimate?
Tycoon Group Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tycoon Group Holdings Limited have?
Tycoon Group Holdings Limited has 894,000,000 shares outstanding.
What happened to Tycoon Group Holdings Limited’s price movement after its last earnings report?
Tycoon Group Holdings Limited reported an EPS of HK$0.026 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.882%.
Which hedge fund is a major shareholder of Tycoon Group Holdings Limited?
Currently, no hedge funds are holding shares in HK:3390
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tycoon Group Holdings Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.38%
Trailing 12-Months
Company Description
Tycoon Group Holdings Limited
Tycoon Group Holdings Limited functions as an investment holding enterprise, specializing in the worldwide distribution and retail of an extensive portfolio of health and wellness products. Its market presence extends across Hong Kong, Mainland China, Macau, and various international regions. The company's operations are divided into three distinct divisions: Distribution, E-Commerce, and physical Retail Stores. It offers a diverse selection of goods, including traditional Chinese medicine, nutritional supplements, skincare, personal care items, and other healthcare solutions, sold under both its proprietary labels and third-party brands. Sales channels encompass wholesale distribution to major chain retailers, independent stores, and traders, alongside direct-to-consumer sales through its own network of brick-and-mortar shops and digital platforms. Founded in 2015, the firm is based in Shatin, Hong Kong.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Kingworld Medicines Group Ltd.
―
PuraPharm Corp. Ltd.
―
New Century Healthcare Holding Co. Ltd.
―
Yestar Healthcare Holdings Co Ltd
―